News Archive

/static/apps/cms/news/1737/LukacsKunkel.jpg

Opsidio, LLC Acquired by Insmed, Advancing Anti-SCF Therapy: From Discovery to Clinical trials

March 13, 2026 / Research

Opsidio, LLC—co-founded by Nicholas W. Lukacs, PhD, Steven Kunkel, PhD, and Cory Hogaboam, PhD—has been acquired by Insmed, which plans to advance the company’s investigational monoclonal antibody INS1148 into Phase 2 studies for interstitial lung disease and moderate-to-severe asthma.

FULL STORY
/static/apps/cms/news/1576/Nunez, Gabriel 500.jpg

New Uses for Common Drug May Help Patients with Inflammatory Diseases

September 19, 2024 / Research

An article recently published by the Nuñez lab provides an exciting discovery for individuals with Alzheimer’s disease, diabetes, and certain other autoimmune diseases caused by aberrant NLRP3. The research, led by Dr. Jie Xu with Drs. Joseph Pickard and Gabriel Nuñez, discovered that a common, safe, FDA-approved drug used to treat alcoholism and cocaine addictions, disulfiram, inhibits the production of NLRP3 inflammasomes. When NLRP3 is activated, it can cause inflammation leading to multiple health issues.

FULL STORY